2 active not recruiting, 2 recruiting, 1 completed, 1 terminated. 6 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 2, Recruiting 2, Completed 1, Terminated 1 |
| Phase 1 | 3 | Active not recruiting 2, Recruiting 1 |
Follow High Grade B-Cell Lymphoma: new trials by email Literature Review of High Grade B-Cell Lymphoma trials Research Report on High Grade B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | OHSU Knight Cancer Institute | 40 | 2024-06-13 | 2026-07-07 |
| Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment Biospecimen Collection, Computed Tomography, Lenalidomide - Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma | Phase 2 | Recruiting | SWOG Cancer Research Network | 227 | 2023-09-26 | 2026-10-28 |
| Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma Bone Marrow Biopsy, Cyclophosphamide, Doxorubicin - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | University of Washington | 33 | 2023-01-26 | 2026-10-30 |
| Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma Acalabrutinib, Axicabtagene Ciloleucel - B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Active not recruiting | University of Washington | 23 | 2020-12-02 | 2026-06-25 |
| Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma Anakinra, Axicabtagene Ciloleucel, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma | Phase 2 | Terminated | Jonsson Comprehensive Cancer Center | 23 | 2020-03-04 | 2026-02-27 |
| Treatment for Advanced B-Cell Lymphoma Rituximab, IT Cytarabine - Diffuse Large Cell Lymphoma, Burkitt's Lymphoma | Phase 2 | Completed | New York Medical College | 45 | 2013-01-01 | 2022-10-25 |
Lymphoma, Large B-Cell, Diffuse (6) · Burkitt Lymphoma (1) · Disease Progression (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Follicular (1) · Lymphoma, Non-Hodgkin (1)
Hemic and Lymphatic Diseases (6) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Lymphatic Diseases (6) · Lymphoproliferative Disorders (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Lymphoma (5) · Lymphoma, B-Cell (5) · Lymphoma, Non-Hodgkin (5) · DNA Virus Infections (1) · Disease Attributes (1) · Epstein-Barr Virus Infections (1) · Herpesviridae Infections (1) · Infections (1)
Cyclophosphamide (3) · Magnetic Resonance Spectroscopy (3) · Disulfides (2) · Doxorubicin (2) · Immunoglobulins (2) · Prednisone (2) · Rituximab (2) · Specimen Handling (2) · Vincristine (2) · axicabtagene ciloleucel (2) · tafasitamab (2) · Biopsy (1) · Etoposide (1) · Fluorodeoxyglucose F18 (1) · Hyaluronoglucosaminidase (1)
University of Washington (2) · Jonsson Comprehensive Cancer Center (1) · New York Medical College (1) · OHSU Knight Cancer Institute (1) · SWOG Cancer Research Network (1)
United States (6)
Ajay Gopal (1) · Jennifer E Amengual (1) · John M Timmerman, MD (1) · Mitchell S Cairo, MD (1) · Stanton Goldman, MD (1) · Stephen D. Smith (1) · Stephen E Spurgeon (1)
U10CA180888 (1)